Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implementation of single low-dose primaquine with routine ACT for uncomplicated falciparum malaria in Burkina Faso, Burundi, and Madagascar
PACTR202504884896166Phase 4Not yet recruiting
- Sponsor
- ReMeD Reseau Medicaments et Developpement
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of primaquine in Malaria and malaria, sponsored by ReMeD Reseau Medicaments et Developpement. Primary endpoints: Severe post-treatment anemia in children younger than 12 years and Severe post-treatment anemia in patients aged 12 years and older. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
primaquine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on PACTR202504884896166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504884896166.